FRLN

Freeline Therapeutics Holdings plc [FRLN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

FRLN Stock Summary

In the News

12:47 29 Mar 2024 FRLN

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024.

07:30 29 Mar 2024 FRLN

Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.

07:30 29 Mar 2024 FRLN

Freeline to Participate in Upcoming Investor Conferences

LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows:

08:53 29 Mar 2024 FRLN

New Strong Buy Stocks for July 14

LE, ING, PD, FRLN and SUNW have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2023.

11:02 29 Mar 2024 FRLN

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

08:00 29 Mar 2024 FRLN

Freeline to Present at 2023 Jefferies Healthcare Conference

LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023.

08:00 29 Mar 2024 FRLN

Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference

LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023.

07:00 29 Mar 2024 FRLN

Freeline to Present at the Stifel Healthcare Conference

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.

09:02 29 Mar 2024 FRLN

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

10:09 29 Mar 2024 FRLN

Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg.

FRLN Financial details

Company Rating
Neutral
Market Cap
28.28M
Income
-49.93M
Revenue
622K
Book val./share
6.89
Cash/share
6.76
Dividend
-
Dividend %
-
Employees
152
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-0.56
Forward P/E
72.11
PEG
0.07
P/S
45.19
P/B
0.94
P/C
0.96
P/FCF
-0.41
Quick Ratio
1.85
Current Ratio
1.95
Debt / Equity
0.13
LT Debt / Equity
0.06
-
-
EPS (TTM)
-11.47
EPS next Y
0.09
EPS next Q
1.58
EPS this Y
-61.82%
EPS next Y
-100.74%
EPS next 5Y
-100.74%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-99.19%
EPS Q/Q
-24.93%
-
-
-
-
SMA20
-
SMA50
-
SMA100
50%
Inst Own
33.76%
Inst Trans
1%
ROA
-101%
ROE
-111%
ROC
-2.14%
Gross Margin
100%
Oper. Margin
-10913%
Profit Margin
-8028%
Payout
-
Shs Outstand
4.36M
Shs Float
26.8M
-
-
-
-
Target Price
-
52W Range
2.11-8.745
52W High
-18.88%
52W Low
+224.5%
RSI
62
Rel Volume
0.19
Avg Volume
28.14K
Volume
5.35K
Perf Week
0.15%
Perf Month
1.41%
Perf Quarter
-
Perf Half Y
64.3%
-
-
-
-
Beta
0.66
-
-
Volatility
0%, 0.03%
Prev Close
0.15%
Price
6.49
Change
0.15%

FRLN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-78.65-127.39-102.09-58.98-22.52
Operating cash flow per share
-60.9-123.64-100.65-45.19-19.8
Free cash flow per share
-69.76-130.78-103.31-46.98-21.57
Cash per share
37.93174.16243.7449.4311.96
Book value per share
54.28200.75264.7550.613.26
Tangible book value per share
54.28200.75264.7350.613.26
Share holders equity per share
54.28200.75264.7550.613.26
Interest debt per share
0.36000-1.11
Market cap
114.26M114.26M258.43M70.69M28.17M
Enterprise value
98.21M40.56M28.46M-46.97M-13.18M
P/E ratio
-3.43-2.12-2.68-0.5-0.32
Price to sales ratio
00000
POCF ratio
-4.43-2.18-2.72-0.66-0.36
PFCF ratio
-3.87-2.06-2.65-0.63-0.33
P/B Ratio
4.971.341.030.590.54
PTB ratio
4.971.341.030.590.54
EV to sales
00000
Enterprise value over EBITDA
-3.06-0.79-0.330.350.14
EV to operating cash flow
-3.81-0.78-0.30.440.17
EV to free cash flow
-3.33-0.73-0.290.420.15
Earnings yield
-0.29-0.47-0.37-1.99-3.16
Free cash flow yield
-0.26-0.48-0.38-1.58-3.03
Debt to equity
00000.11
Debt to assets
00000.07
Net debt to EBITDA
0.51.432.70.880.43
Current ratio
2.857.1613.726.22.18
Interest coverage
-271.40009.55
Income quality
0.770.970.990.770.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0000-0.02
Capex to operating cash flow
0.150.060.030.040.09
Capex to revenue
00000
Capex to depreciation
-3.86-1.96-1.31-1.79-4.03
Stock based compensation to revenue
00000
Graham number
309.93758.55779.83259.1381.98
ROIC
-1.79-0.75-0.41-1.19-1.54
Return on tangible assets
-1.04-0.55-0.36-0.99-1.01
Graham Net
32.94166.16238.2442.795.77
Working capital
16.93M76.61M239.36M107.61M36.66M
Tangible asset value
22.93M84.91M249.78M120.43M53.74M
Net current asset value
16.93M76.61M239.36M107.61M33.4M
Invested capital
00000.11
Average receivables
010.25M13.81M9.16M1.72M
Average payables
03.72M6.96M6.64M7.62M
Average inventory
0729K1.96M4.75M12.03M
Days sales outstanding
00000
Days payables outstanding
01.37K1.53K792.252.11K
Days of inventory on hand
0198.74583.13980.273.7K
Receivables turnover
00000
Payables turnover
00.270.240.460.17
Inventory turnover
01.840.630.370.1
ROE
-1.45-0.63-0.39-1.17-1.7
Capex per share
-8.86-7.14-2.66-1.8-1.78

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.140
Net income per share
-3.44-5.310.27-3.69-2.77
Operating cash flow per share
-3.5-4.59-4.25-3.98-1.99
Free cash flow per share
-4-5.49-4.34-4.04-1.99
Cash per share
15.210.9212.768.936.76
Book value per share
15.8312.1112.899.676.89
Tangible book value per share
15.8312.1112.899.676.89
Share holders equity per share
15.8312.1112.899.676.89
Interest debt per share
2.832.84-7.781.10.92
Market cap
45.49M30.86M29.66M11.21M18.74M
Enterprise value
-8.4M-10.49M-20.37M-22.79M-6.72M
P/E ratio
-0.76-0.346.36-0.17-0.39
Price to sales ratio
00018.163.75K
POCF ratio
-3-1.55-1.61-0.65-2.16
PFCF ratio
-2.62-1.3-1.57-0.64-2.16
P/B Ratio
0.660.590.530.270.62
PTB ratio
0.660.590.530.270.62
EV to sales
000-36.94-1.34K
Enterprise value over EBITDA
0.370.650.541.190.58
EV to operating cash flow
0.550.531.11.320.78
EV to free cash flow
0.480.441.081.30.77
Earnings yield
-0.33-0.750.04-1.43-0.65
Free cash flow yield
-0.38-0.77-0.64-1.56-0.46
Debt to equity
0.170.110.10.110.13
Debt to assets
0.120.070.070.080.08
Net debt to EBITDA
2.392.581.331.782.2
Current ratio
3.312.182.812.451.95
Interest coverage
-79.42-3.110.5100
Income quality
1.020.86-15.821.080.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00015.391.28K
Research and developement to revenue
00014.311.16K
Intangibles to total assets
0-0.02000
Capex to operating cash flow
0.140.20.020.010
Capex to revenue
000-0.41-1.2
Capex to depreciation
-5.36-12.37-1.23-0.59-0.02
Stock based compensation to revenue
0001.74179
Graham number
34.9938.058.8328.3320.74
ROIC
-0.25-0.31-0.26-0.3-0.32
Return on tangible assets
-0.15-0.260.01-0.26-0.25
Graham Net
8.915.277.624.842.93
Working capital
51.69M36.66M41.13M27.13M16.52M
Tangible asset value
68.58M53.74M55.99M42.02M30.04M
Net current asset value
42.61M33.4M38.49M25.18M14.82M
Invested capital
0.170.110.10.110.13
Average receivables
2.81M2.1M1.38M2.32M2.97M
Average payables
8.92M10.01M11.26M9.66M7.33M
Average inventory
3.09M10.84M10.71M2.42M914.5K
Days sales outstanding
000454.9650.81K
Days payables outstanding
2.23K2.85K3.47K1.42K1.82K
Days of inventory on hand
904.165K1.05K219.82180.11
Receivables turnover
0000.20
Payables turnover
0.040.030.030.060.05
Inventory turnover
0.10.020.090.410.5
ROE
-0.22-0.440.02-0.38-0.4
Capex per share
-0.5-0.9-0.09-0.060

FRLN Frequently Asked Questions

What is Freeline Therapeutics Holdings plc stock symbol ?

Freeline Therapeutics Holdings plc is a GB stock and trading under the symbol FRLN

What is Freeline Therapeutics Holdings plc stock quote today ?

Freeline Therapeutics Holdings plc stock price is $6.49 today.

Is Freeline Therapeutics Holdings plc stock public?

Yes, Freeline Therapeutics Holdings plc is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap